Alpha 2.0
Login Register
» Authors » F Perrone

F Perrone

Explore the profile of F Perrone including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 163
Citations 2156
Followers 0
Related Specialties
Oncology
Endocrinology
General Medicine
Top 10 Co-Authors
C Gallo
S De Placido
M Di Maio
C Gridelli
S Pignata
A R Bianco
C Carlomagno
A Morabito
R Lauria
M De Laurentiis
Published In
Ann Oncol
Br J Cancer
ESMO Open
Eur J Cancer
Cancer Treat Rev
Affiliations
Soon will be listed here.
Recent Articles
11.
Resistance to osimertinib in advanced EGFR-mutated NSCLC: a prospective study of molecular genotyping on tissue and liquid biopsies
Leonetti A, Verze M, Minari R, Perrone F, Gnetti L, Bordi P, et al.
Br J Cancer . 2023 Nov; 130(1):135-142. PMID: 37938348
Background: Resistance to osimertinib in advanced EGFR-mutated non-small cell lung cancer (NSCLC) constitutes a significant challenge for clinicians either in terms of molecular diagnosis and subsequent therapeutic implications. Methods: This...
12.
ESMO Guidance for Reporting Oncology real-World evidence (GROW)
Castelo-Branco L, Pellat A, Martins-Branco D, Valachis A, Derksen J, Suijkerbuijk K, et al.
Ann Oncol . 2023 Oct; 34(12):1097-1112. PMID: 37848160
No abstract available.
13.
Corrigendum to "Optimizing choices and sequences in the diagnostic-therapeutic landscape of advanced triple-negative breast cancer: An Italian consensus paper and critical review" [Cancer Treat. Rev. 114 (2023) 102511]
Miglietta F, Fabi A, Generali D, Dieci M, Arpino G, Bianchini G, et al.
Cancer Treat Rev . 2023 Jul; 119:102594. PMID: 37400291
No abstract available.
14.
Cancer care in transgender and gender-diverse persons: results from two national surveys among providers and health service users by the Italian Association of Medical Oncology
Leone A, Miceli R, Trapani D, Massagrande M, Morano F, Marsoni S, et al.
ESMO Open . 2023 Jun; 8(3):101578. PMID: 37270870
Background: Transgender and gender-diverse (TGD) population represents an underserved group across the cancer care continuum. To assess the perspective of both oncology health care providers (OHPs) and TGD individuals in...
15.
Corrigendum to "Optimizing choices and sequences in the diagnostic-therapeutic landscape of advanced triple-negative breast cancer: An Italian consensus paper and critical review" [Cancer Treatm. Rev. 114 (2023) 102511]
Miglietta F, Fabi A, Generali D, Dieci M, Arpino G, Bianchini G, et al.
Cancer Treat Rev . 2023 May; 117:102570. PMID: 37150120
No abstract available.
16.
Optimizing choices and sequences in the diagnostic-therapeutic landscape of advanced triple-negative breast cancer: An Italian consensus paper and critical review
Miglietta F, Fabi A, Generali D, Dieci M, Arpino G, Bianchini G, et al.
Cancer Treat Rev . 2023 Jan; 114:102511. PMID: 36638600
Triple-negative (TN) metastatic breast cancer (mBC) represents the most challenging scenario withing mBC framework, and it has been only slightly affected by the tremendous advancements in terms of drug availability...
17.
Subgroup analyses in randomized phase III trials of systemic treatments in patients with advanced solid tumours: a systematic review of trials published between 2017 and 2020
Paratore C, Zichi C, Audisio M, Bungaro M, Caglio A, Di Liello R, et al.
ESMO Open . 2022 Oct; 7(6):100593. PMID: 36228332
Background: Subgroup analyses of randomized controlled trials are very common in oncology; nevertheless, the methodological approach has not been systematically evaluated. The present analysis was conducted with the aim of...
18.
Alternative academic approaches for testing homologous recombination deficiency in ovarian cancer in the MITO16A/MaNGO-OV2 trial
Capoluongo E, Pellegrino B, Arenare L, Califano D, Scambia G, Beltrame L, et al.
ESMO Open . 2022 Sep; 7(5):100585. PMID: 36156447
Background: The detection of homologous recombination deficiency (HRD) can identify patients who are more responsive to platinum and poly ADP ribose polymerase inhibitors (PARPi). MyChoice CDx (Myriad) is the most...
19.
Position paper of the Italian Association of Medical Oncology on the impact of COVID-19 on Italian oncology and the path forward: the 2021 Matera statement
Beretta G, Casolino R, Corsi D, Perrone F, Di Maio M, Cinieri S, et al.
ESMO Open . 2022 Aug; 7(4):100538. PMID: 35921761
The coronavirus disease 2019 (COVID-19) pandemic has severely affected cancer care and research by disrupting the prevention and treatment paths as well as the preclinical, clinical, and translational research ecosystem....
20.
The role of patient-reported outcome measures in the continuum of cancer clinical care: ESMO Clinical Practice Guideline
Di Maio M, Basch E, Denis F, Fallowfield L, Ganz P, Howell D, et al.
Ann Oncol . 2022 Apr; 33(9):878-892. PMID: 35462007
No abstract available.